Citadel Advisors
COGT icon

Citadel Advisors’s Cogent Biosciences COGT Stock Holding History

Citadel Advisors’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.91M Buy
101,600
+28,500
+39% +$1.05M ﹤0.01% 4757
2025
Q4 		$2.6M Buy
73,100
+61,000
+504% +$1.71M ﹤0.01% 5441
2025
Q3 		$174K Sell
12,100
-38,300
-76% -$454K ﹤0.01% 11404
2025
Q2 		$362K Buy
50,400
+42,000
+500% +$233K ﹤0.01% 9376
2025
Q1 		$50.3K Sell
8,400
-31,900
-79% -$250K ﹤0.01% 12310
2024
Q4 		$314K Buy
40,300
+2,100
+5% +$20.9K ﹤0.01% 9561
2024
Q3 		$413K Buy
38,200
+1,600
+4% +$15.6K ﹤0.01% 8673
2024
Q2 		$309K Buy
36,600
+8,800
+32% +$66.7K ﹤0.01% 9081
2024
Q1 		$187K Sell
27,800
-18,700
-40% -$116K ﹤0.01% 10428
2023
Q4 		$273K Buy
46,500
+26,600
+134% +$204K ﹤0.01% 9339
2023
Q3 		$194K Buy
19,900
+4,000
+25% +$47.4K ﹤0.01% 9969
2023
Q2 		$188K Buy
15,900
+2,900
+22% +$33.3K ﹤0.01% 9989
2023
Q1 		$140K Sell
13,000
-23,900
-65% -$306K ﹤0.01% 10750
2022
Q4 		$427K Sell
36,900
-11,100
-23% -$138K ﹤0.01% 8573
2022
Q3 		$716K Sell
48,000
-10,700
-18% -$147K ﹤0.01% 7706
2022
Q2 		$529K Buy
+58,700
New +$401K ﹤0.01% 8520

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors's COGT Position: Q1 2026 in Review

Citadel Advisors increased its Cogent Biosciences (COGT) stake by 19% in Q1 2026, buying an estimated $10.2M and bringing the position to 1,714,927 shares worth $66M. The position accounts for 0.01% of the portfolio, ranked #1121.

Citadel Advisors first reported a position in COGT in Q1 2018 and has held it in 26 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Citadel Advisors held 1,714,927 shares of Cogent Biosciences worth $66M as of Q1 2026.
  • Citadel Advisors bought 275,933 Cogent Biosciences shares in Q1 2026, an estimated $10.2M.
  • Cogent Biosciences made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1121 holding.
  • Citadel Advisors first reported a position in Cogent Biosciences in Q1 2018 and has held it in 26 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.